France 2017: More Price Cuts, Rebates, Generics and Biosimilars, And A New Innovation Fund
Executive Summary
The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.